AIDS: Caused by development of resistance to drugs in a non-target intracellular parasite

Medical Hypotheses

Volumn 68, Issue 1, 2007, Pages 151-157

  Parris, George E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE; 8 AMINOQUINOLINE DERIVATIVE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; CHLOROQUINE; PAMAQUINE; PLASMOQUINE; PRIMAQUINE; SONTOQUINE; TOXIC SUBSTANCE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; BACTERIUM; CELL SECRETION; CELLULAR IMMUNITY; CENTRAL AFRICA; DISEASE TRANSMISSION; DRUG EXPOSURE; DRUG RESISTANCE; ENDEMIC DISEASE; FUNGUS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOTHESIS; MALARIA; NONHUMAN; PLASMODIUM; PRIMATE; PRIORITY JOURNAL; PROTOZOON; RETROVIRUS; SIMIAN VIRUS; SYMBIOSIS; T LYMPHOCYTE; VIRUS RESISTANCE;

PRIMATES; SIMIAE;

EID: 33750630088     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.06.011     Document Type: Article

References (40)

1. Korber B., Muldoon M., Theiler J., et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288 (2000) 1789-1796
2. Hooper E. The River (1999), Little Brown, Boston
3. Kalish M.L., Wolfe N.D., Ndongmo C.B., et al. Central African hunters exposed to simian immunodeficiency virus. Emerg Infect Dis 11 (2005) 1928-1930
4. Marx P.A., Apetrei C., and Drucker E. AIDS as a zoonosis? Confusion over the origin of the virus and the origin of the epidemics. J Med Primatol 33 (2004) 220-226
5. Badley A.D., Roumier T., Lum J.J., and Kroemer G. Mitochondrion-mediated apoptosis in HIV-1 infection. Trends Pharmacol Sci 24 (2003) 298-305
6. Parris G.E. Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites. Med Hypotheses 62 (2004) 354-357
7. Parris G.E. Update on hypothesis linking chloroquine-resistant malaria to disease-causing HIV. Med Hypotheses 67 (2006) 670-671
8. Parris G.E. The timing is right: Evolution of AIDS-causing HIV strains is consistent with history of chloroquine use. Med Hypotheses 67 (2006) 1258-1259
9. Asin S., Bren G.D., Carmona E.M., Solan N.J., and Pava C.V. NF-kappaB cis-acting motifs of the human immunodeficiency virus (HIV) long terminal repeat regulate HIV transcription in human macrophages. J Virol 75 (2001) 11408-11416
10. Zabel U., Schreck R., and Baeuerle P.A. DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. J Biol Chem 226 (1991) 252-260
11. Pardridge W.M., Yang J., and Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett 64 (1998) 45-47
12. Weber S.M., and Levitz S.M. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 165 (2000) 1534-1540
13. Paxton L.L.L., Li L.-J., and Secor V. Flanking sequences for the human intercellular adhesion molecule-1 NF-κB response element are necessary for tumor necrosis factor α-induced gene expression. JBC 272 (1997) 15928-15935
14. D'Alessandro U., and Buttiens H. History and importance of antimalarial drug resistance. Trop Med Int Health 6 (2001) 845-848
15. Levin B.R. The evolution and maintenance of virulence in microparasites. Emerg Infect Dis 2 (1996) 930102
16. Goubau P., Vandamme A.M., and Desmvter J. Questions on the evolution of primate T-lymphotropic viruses raised by molecular and epidemiological studies of divergent strains. J Acquir Immune Defic Syndr Retrovirol 13 (1996) 5242-5247
17. Van Dooren S., Salemi M., and Vandamme A.M. Dating the origin of the African human T-cell lymphotropic virus type-i (HTLV-I) subtypes. Mol Biol Evol 18 (2001) 661-671
18. Napravnik S., Edwards D., Stewart P., et al. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 40 (2005) 34-40
19. Kristiansen T.B., Pedersen A.G., Eugen-Olsen J., Katzenstein T.L., and Lundgren J.D. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand J Infect Dis 37 (2005) 890-901
20. Savarino A., Boelaert J.R., Cassone A., Majori G., and Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 3 (2003) 722-727
21. Savarino A., Lucia M.B., Rastrelli E., et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35 (2004) 223-232
22. Rayne F., Vendeville A., Bonhoure A., and Beaumelle B. The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity. J Virol 78 (2004) 12054-12057
23. Vincent M.J., Bergeron E., Benjannet S., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2 (2005) 69
24. Salemi M., Strimmer K., Hall W.W., et al. Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. FASEB J 15 (2001) 276-278
25. Sweeney A.W., Blackburn C.R.B., and Rieckmann K.H. Short report: the activity of pamaquine, an 8-aminoquinoline drug, against sporozolite-induced infections of Plasmodium vivax (New Guinea strains). Am J Trop Med Hyg 71 (2004) 187-189
26. Van den Braden F., and Henry E. Nouvelle medication du paludisme par la plasmoquine. Bull Soc Pathol Exot 20 (1927) 728-734
27. Malaria Commission (of the League of Nations). The treatment of malaria, Section B. Treatment of malaria with plasmoquine and quiniostovarsol, vol. 188; 1932. p. 9-35.
28. Rice JB. Sworn testimony regarding the early history of chloroquine in the case of Sterling Drug, Inc. v. Yarrow, 408 F.2d 978, 8th circa 1969.
29. Naets JP. Paludisme essais de chloroquine (SN7618). Rapport sur l'activite durant les annees 1946 et 1947. Fonds Reine Elisabeth pour l'Assistance Medicale aux Indigenes du Congo Belge (FOREAMI), Bruxelles, 1948. p. 136-7.
30. Doucet G. Note preliminaire sur l'emploi du SN7618 en milieu malarian hyperendemique. Ann Soc Med Trop 27 (1947) 341-346
31. World Health Organization Nuclear Committee on Malaria. Note on proposed appropriation of a sum of $15,000 earmarked: field work during 1947 malaria season, 21 March 1947. p. 1-3.
32. World Health Organization Expert Committee on Malaria. Report on the first session 22-25 April 1947, 30 June 1947. p. 8-14.
33. World Health Organization Expert Committee on Malaria. Note on coordinated experiments on suppressive prophylaxis for malaria with new synthetic drugs, 4 April 1947. p. 1-2.
34. Moran J.S., and Bernard K.W. The spread of chloroquine-resistant malaria in Africa. Implications for travelers. JAMA 262 (1989) 245-248
35. Lemey P., Pybus O.G., Wang B., Saksena N.K., Salemi M., and Vandamme A.M. Tracing the origin and history of the HIV-2 epidemic. Proc Natal Acad Sci U.S.A. 100 (2003) 6588-6592
36. Vijgen L., Keyaerts E., Moes E., et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol 79 (2005) 1595-1604
37. Pourrut X., Kumulungui B., Wittmann T., et al. The natural history of Ebola virus in Africa. Microbes Infect 7 (2005) 1005-1014
38. Bray M., and Geisbert T.W. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37 (2005) 1560-1566
39. Yuste E., Sanchez-Palomino S., Casado C., Domingo E., and Lopez-Galindez E. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol 73 (1999) 2745-2751
40. Escarmis C., Davila M., and Domingo E. Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet. J Mol Biol 285 (1999) 495-505